Here are the 10-K annual reports from Cingulate Inc. (CING) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CING and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CING filings page.
Cingulate Inc. is a biopharmaceutical company developing next‑generation, once‑daily treatments using its Precision Timed Release (PTR) platform. Its lead ADHD candidate, CTx‑1301, has an NDA under FDA review with a PDUFA target action date of May 31, 2026.
CTx‑1301 aims to provide rapid onset within 30 minutes and full active‑day coverage, potentially avoiding afternoon booster doses. The company is also advancing ADHD candidate CTx‑1302 and anxiety candidate CTx‑2103, both built on the same PTR technology, and holds patents expected to provide protection into the 2030s and early 2040s.